Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. - Wikidata - wikimedia - TriplyDB

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

http://www.wikidata.org/entity/Q34157346

about

Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors Juvenile Idiopathic Arthritis in the Era of International Cooperation.What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Summary of worldwide pediatric malignancies reported after exposure to etanercept.Nutritional supplementation and dietary restriction in the resolution of enthesitis-related arthritis.Juvenile idiopathic arthritis-associated uveitis.The development and assessment of biological treatments for children.Current medical treatments for juvenile idiopathic arthritis.Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain.A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide.Rates of malignancy associated with juvenile idiopathic arthritis and its treatment Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study Erosion or normal variant? 4-year MRI follow-up of the wrists in healthy children Update on the treatment of juvenile idiopathic arthritis Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Biologics in children's autoimmune disorders: efficacy and safety.Emerging drugs to treat juvenile idiopathic arthritis.Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.Optimization of pediatric rheumatology therapeutics.Update on biologicals for treatment of juvenile idiopathic arthritis.Infectious complications in juvenile idiopathic arthritis.Biologic response modifiers and pediatric psoriasis.Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.Biologic-associated infections in pediatric rheumatology.Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.Management of Juvenile Idiopathic Arthritis: A Clinical Guide.Juvenile idiopathic arthritis: management and therapeutic options.Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.MRI of the wrist in juvenile idiopathic arthritis: erosions or normal variants? A prospective case-control study.Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version).

P2860

Q29302324-E65FC94C-75FC-4155-9FB3-AB9F71418BA4 Q30235998-D4AAA978-CA74-40ED-A5DF-3EE0C24A1CEF Q33765738-F43E22EA-8FB4-4C67-904E-2B8B6F70A263 Q33998050-D1C9C383-A5FD-4DF0-9417-2F747E6F8F81 Q34904542-0B92ED45-D4D6-473E-9B5C-4F15DD519372 Q34950552-C8CBB1DC-59DE-4F43-8B08-7053C616C99C Q35135936-9D37A7D4-3E2F-441B-A75E-87640542427D Q35294398-3E0100E2-031C-4D64-9113-E242FCA46926 Q35654296-3549C86D-8161-4E36-AF68-F3B7ABD93803 Q35795354-D4576927-9376-4B76-8954-1422F763A9A6 Q35824809-E654297E-419E-4658-A445-DBC0463B2B3C Q35861269-11A503E7-466D-4356-9FE2-B367E6353434 Q36513512-6B6283FF-7C75-41FA-88EB-416BEF9EFCBD Q36620571-3F86E3BB-990A-4560-8E14-FC70487A9249 Q37060351-EF609516-21A1-4B76-864F-D774D13133A5 Q37147226-28E9F139-BAF3-408A-B90E-9A2AF94A9542 Q37320554-1F57E96B-5BAD-446A-A67B-940974873591 Q37463702-2ED8AC2F-C7E5-4D5A-8B57-3C407561E6D6 Q37765830-B84408E6-5C18-4700-A36A-B4348A2C8E13 Q37870209-0E507B40-0AE1-43B1-94C5-4E256D069EAD Q37894016-63D21F77-AFEF-4B88-8160-B933756164BF Q37991520-DEB12535-F769-4745-89B4-00310015EBE5 Q38071693-430E4D86-0A49-4EA2-8C40-DC94A2FC23EC Q38093095-6199CA2F-30A7-45E9-B83D-7C3ED7807556 Q38366432-FC349C4C-A003-434A-80EA-14824BBAF6ED Q38530469-16209AAB-09C1-4BA2-9ACD-02334340B757 Q38589392-F7BA8B93-9A97-4611-A170-4599F66A5C2D Q38591278-8D81DCED-B3C6-4200-AD2A-13DDBA201F98 Q38711172-627E959F-18AB-4F5E-B2A2-3959B67459DC Q38916421-65965C74-F096-4830-92BF-5305329E2838 Q39243858-58B7BF87-889E-4F38-BE53-651F047464C2 Q39371316-016B7C08-5EDC-45FD-84F3-4E81ACA4DA9F Q40179129-F131AC38-0EC2-46A5-8068-34AFEF3BD5AA Q40179378-7DC214A2-4457-4977-B8F5-2054ECF1B9F5 Q41600541-7C22CBFB-20C0-4253-AA60-CDCAF2FE6627 Q45535646-EF55ADF3-C3F3-4F72-8415-8B90E51FE094 Q48505199-A435FB39-0E22-4414-B8E5-894C596AA284 Q50065301-452C0A48-BB72-4AAA-8503-CFBC6308925F Q51550151-4A7D42B3-F201-438B-93CA-951820EDB8C8 Q54144614-8205D8B7-CC3D-4E4D-B33C-33B6DACCDE52

P2860

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

http://www.wikidata.org/entity/Q34157346

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Long-term efficacy and safety ...... pen-label treatment extension.

@ast

Long-term efficacy and safety ...... pen-label treatment extension.

@en

Long-term efficacy and safety ...... pen-label treatment extension.

@nl

type

label

Long-term efficacy and safety ...... pen-label treatment extension.

@ast

Long-term efficacy and safety ...... pen-label treatment extension.

@en

Long-term efficacy and safety ...... pen-label treatment extension.

@nl

prefLabel

Long-term efficacy and safety ...... pen-label treatment extension.

@ast

Long-term efficacy and safety ...... pen-label treatment extension.

@en

Long-term efficacy and safety ...... pen-label treatment extension.

@nl

P1433

Q34157346-F7A07709-4C64-4653-8388-E9524BC51AF2

P1476

Q34157346-CBC3B2A9-3495-4558-ADB9-8A03CDE43507

P2093

Q34157346-00F28C14-FBE4-455A-B505-6DEFF9D26654

Q34157346-00F68AC1-A1E4-42E5-8A7E-D84649FE8C2B

Q34157346-10035A75-026F-49DF-9EF7-D38B5B58E82A

Q34157346-18E0C66F-AD44-4B96-AE89-3FAA7192E0BE

Q34157346-2AD8B901-1264-4309-BBE5-A6DFC53EF536

Q34157346-3A10F7FA-F29E-4567-824B-93551F6D0F38

Q34157346-4F3B69BE-05E5-4A80-96FE-1890771C344E

Q34157346-526EF240-684F-4F51-A920-39C7114A4511

Q34157346-52B68469-3C31-4939-B256-466C6F7B9165

Q34157346-55BC66C1-662C-49E1-96BF-F886F8FA200D

P2860

Q34157346-37F08897-C80A-452F-9D78-8FC581472511

Q34157346-40C813E1-E736-4AB3-B3CD-50E7EB7447A6

Q34157346-4672BA45-BCFA-48AA-9DA8-CBF0F5CB5B5B

Q34157346-4CDB0E13-10BB-4E9A-BC70-56D7E81B188D

Q34157346-6D7D3F50-87B3-471B-A592-D9B97B764825

Q34157346-8F8D46EC-5A56-49BF-9108-8C74DF64CD33

Q34157346-91F9C657-50BB-4D1A-94B8-D8E0ED60D7EF

Q34157346-A4C9F44E-CE7C-4CDD-89CC-B1F965461FD9

Q34157346-EB48F387-F8FD-48C3-B957-571DD898BE54

P304

Q34157346-FD03A0F5-1956-4235-A70D-E347B3AE473A

P31

Q34157346-87F20ADA-367E-4623-88E1-970C487C0507

P356

Q34157346-1847F5BD-F402-4740-AACF-50DE34989B1F

P407

Q34157346-9C9D1D3E-821A-4BB3-B8BE-21858820D4D7

P433

Q34157346-E12EE107-1A8D-4981-96AE-053CA174DA81

P478

Q34157346-BA88E125-F927-4C5E-A772-9ADF44B4B48B

P50

Q34157346-2F262DB1-CC27-46D7-A7AF-87B8B0B5E60C

Q34157346-42F00731-76B4-4429-8169-AD8CF4378B4A

P577

Q34157346-0FC70F53-FC60-40E6-8694-43CB80441396

P5875

Q34157346-384012C9-465C-4BD7-AF60-ADC84DCEADD6

P698

Q34157346-77E342D7-8310-46AC-8276-A965792529BA

P932

Q34157346-1C274E16-299F-4FE6-90D6-AFE2C9296CAE

P356

ARD.2009.100354

P1433

Annals of the Rheumatic Diseases

P1476

Long-term efficacy and safety ...... open-label treatment extension

@en

P2093

Adedigbo Fasanmade

http://www.w3.org/2001/XMLSchema#string

Alan Mendelsohn

http://www.w3.org/2001/XMLSchema#string

Alberto Martini

http://www.w3.org/2001/XMLSchema#string

Daniel J Lovell

http://www.w3.org/2001/XMLSchema#string

Earl D Silverman

http://www.w3.org/2001/XMLSchema#string

Edward H Giannini

http://www.w3.org/2001/XMLSchema#string

Ivan Foeldvari

http://www.w3.org/2001/XMLSchema#string

Joachim Oppermann

http://www.w3.org/2001/XMLSchema#string

Joyce Davidson

http://www.w3.org/2001/XMLSchema#string

Lisa Imundo

http://www.w3.org/2001/XMLSchema#string

P2860

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology.

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group

Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.

Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group.

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

P304

718-722

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2009.100354

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Gabriele Simonini

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42255187

http://www.w3.org/2001/XMLSchema#string

P698

20237125

http://www.w3.org/2001/XMLSchema#string

P932

2946101

http://www.w3.org/2001/XMLSchema#string